Vanderbilt Report: Full Alliance Group helps Power Hypochlorous Acid's Breakout from Hospitals to the Global Consumer Market
MWN-AI** Summary
The Vanderbilt Report highlighted the innovative growth of hypochlorous acid (HOCl), a compound historically confined to hospital use, driven by Full Alliance Group Inc. (OTC: FAGI) and its subsidiary, Aquaox Pure Solutions. Once regarded merely as a reliable disinfectant, HOCl is now transforming into a versatile platform chemical with applications spanning healthcare, consumer products, veterinary uses, and agriculture.
The global market for HOCl surged from $8.96 billion in 2024, with projections reaching $11.80 billion by 2034, largely due to its adoption in wellness, skincare, and animal-care sectors. Breaking out of its medical confines, HOCl products, such as the alcohol-free face spray JUSSPRAY™, are becoming popular among health-conscious consumers, especially millennials influenced by social media trends. Endorsements from medical professionals, including board-certified vascular surgeon Dr. Richard M. Goldfarb, have further bolstered the credibility and consumer acceptance of HOCl.
Moreover, HOCl is making strides in veterinary and agricultural fields, where it is used for treating wounds and improving livestock health while supporting organic farming initiatives due to its non-toxic and environmentally safe properties. Aquaox’s recent contract for livestock care in Spain signifies its growing global influence.
The infrastructure supporting Aquaox’s expansion is impressive, with their Tampa, FL facility producing over 155,000 units in just one quarter, ensuring efficient distribution across various markets. This capacity positions the company to meet rising demand effectively, whether aimed at retail consumers or international distributors.
Overall, the report underscores the significant potential of HOCl, reflecting a shift towards sustainable, health-focused products across multiple industries.
MWN-AI** Analysis
The recent report highlighting Full Alliance Group Inc. (OTC: FAGI) underscores a significant opportunity for investors in the booming hypochlorous acid (HOCl) market. As HOCl transitions from a hospital mainstay to a multifunctional solution in various sectors—especially consumer wellness, veterinary, and agriculture—it is crucial for investors to consider the implications of this transformation.
The market for HOCl is poised for substantial growth, projected to expand from $8.96 billion in 2024 to $11.80 billion by 2034. Factors driving this surge include increasing demand for safe, environmental, and effective wellness products. Aquaox Pure Solutions, a subsidiary of FAGI, is well-positioned to capture this momentum with innovative products like the alcohol-free JUSSPRAY™, which benefit from credible endorsements by medical professionals. This kind of market validation enhances consumer trust, a vital component for any emerging consumer brand.
Additionally, the application of HOCl in veterinary and agricultural markets adds a new dimension to its revenue potential, especially as the agricultural sector shifts towards sustainable practices. Aquaox's recent contract in Spain exemplifies its capability to penetrate international markets and highlight HOCl's efficacy over traditional options like bleach.
Investors should note the robust production capacity of Aquaox, with over 155,000 units manufactured in a recent quarter, signaling strong operational efficiency and the ability to meet growing demand dynamically.
However, potential investors should exercise caution. The report includes forward-looking statements subject to market volatility and regulatory changes. Conducting thorough due diligence and consulting with financial advisors remain paramount before making investment decisions in such a rapidly evolving industry. In essence, FAGI offers an intriguing investment prospect within a transformative market landscape, but careful strategy is advisable.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BRISTOL, Tenn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Once relegated to the back rooms of hospitals, hypochlorous acid (HOCl) is rapidly becoming one of the most disruptive platform chemicals of the decade and Full Alliance Group Inc. (OTC: FAGI) is helping lead that charge through its wholly owned subsidiary, Aquaox Pure Solutions.
This transformation from sterile disinfectant to multi-industry powerhouse is redefining how a single molecule can scale across healthcare, consumer wellness, veterinary, and agricultural markets.
From Hospital Hallways to Consumer Hands
HOCl spent decades as a hospital staple, reliable, effective, and often overlooked. But with recent advances in on-site generation and contract manufacturing, it’s now reaching everyday consumers at scale.
The global HOCl market surged from $8.96 billion in 2024 and is projected to hit $11.80 billion by 2034, fueled by explosive growth in wellness, skincare, and animal care applications.
“Few chemicals cross industry boundaries this fast,” said a company spokesperson. “HOCl isn’t just a disinfectant anymore, it’s a platform.”
Consumer Wellness: A Viral Shift
TikTok trends and medical endorsements have catapulted HOCl into the mainstream. Alcohol-free face sprays like JUSSPRAY™, produced by Aquaox, are resonating with health-conscious consumers looking for gentle, dermatologist-approved alternatives.
Board-certified vascular surgeon Dr. Richard M. Goldfarb called the brand “Doctor Recommended and Doctor Approved,” lending critical credibility to HOCl’s consumer expansion.
With consumers demanding cleaner, safer, and sustainable wellness products, HOCl’s natural origin and antimicrobial efficacy have made it a go-to choice, especially in skincare, wound care, and home sanitation.
Beyond Humans: Veterinary & Agricultural Expansion
HOCl’s evolution didn’t stop at skincare. Farmers and veterinarians now use HOCl to treat wounds, clean surgical sites, and replace antibiotics in livestock operations. Organic farms have embraced it for its safety profile and environmental benefits.
Aquaox recently secured its first European agricultural contract for livestock umbilical cord care in Spain, a major validation of the molecule’s global veterinary potential.
Its 90x efficacy over bleach and non-toxic nature make it ideal for sustainable farming, which continues to be a fast-growing global priority.
Manufacturing at Scale
Behind this expansion is Aquaox’s robust contract manufacturing infrastructure. The company’s Tampa, FL facility recently produced over 155,000 units in a single quarter, spanning everything from 2 oz travel sprays to gallon-size industrial containers.
This scale enables rapid deployment across sectors, whether targeting retail consumers, institutional buyers, or international distributors.
About Vanderbilt Report
Vanderbilt Report is a financial news and content platform. The information contained in this release is for informational purposes only and should not be considered an offer to buy or sell securities. All material is provided “as is” without any warranty of any kind.
Media Contact
Kristen Owens
Disclosure:
This press release is a paid communication. Vanderbilt Report (a property of AB Holdings, LLC) has received compensation from the company or a third party for the preparation and distribution of this content. The information herein should not be construed as investment advice. Investors are encouraged to conduct their own due diligence and consult with a licensed financial advisor before making any investment decisions.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Readers should not place undue reliance on such statements, which speak only as of the date of this release.
FAQ**
How does Full Alliance Group Inc. (FAGI) plan to capitalize on the projected growth of the hypochlorous acid market, which is anticipated to reach $11.80 billion by 2034?
What specific strategies is Full Alliance Group Inc. (FAGI) employing to expand Aquaox Pure Solutions’ product offerings in healthcare and consumer wellness sectors?
Can Full Alliance Group Inc. (FAGI) provide insights on the impact of TikTok trends and medical endorsements on consumer adoption of its HOCl products, particularly JUSSPRAY™?
How is Full Alliance Group Inc. (FAGI) ensuring scalability in its manufacturing processes to meet the increasing demand for hypochlorous acid across diverse markets, including agricultural applications?
**MWN-AI FAQ is based on asking OpenAI questions about Full Alliance Group Inc (OTC: FAGI).
NASDAQ: FAGI
FAGI Trading
-15.57% G/L:
$0.032 Last:
38,200 Volume:
$0.03585 Open:
